# Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

| Name o  | fentity  |  |
|---------|--|--|
| Southe  | rn Cross Electrical Engineering Lim                        | ited   |
|         |  |  |
| ABN     |  |  |
| 92 009  | 307 046  |  |
|         |  |  |
| We (th  | ne entity) give ASX the following                          | information.   |
|         | 7. 0   |  |
|         |  |  |
| Part '  | 1 - All issues   |  |
| You mus | st complete the relevant sections (attach                  | sheets if there is not enough space).  |
|         | *Class of *securities issued or to                         | Financial Voar 2019 Performance Bights granted   |
| 1       | be issued  | Financial Year 2018 Performance Rights granted under the Southern Cross Electrical Engineering |
|         | 50 135 <b>404</b>  | Limited Senior Management Long Term Incentive  |
|         |  | Plan.  |
|         | N 1 C+ 1   | 1 241 110  |
| 2       | Number of *securities issued or to be issued (if known) or | 1,241,118  |
|         | maximum number which may be                                |  |
|         | issued   |  |
|         |  |  |
|         |  |  |

<sup>+</sup> See chapter 19 for defined terms.

Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)

#### The key terms of the FY18 Performance Rights are:

- to be performance tested over a three year period from 1 July 2017 to 30 June 2020. No Performance Rights will vest until 30 June 2020.
- performance testing criteria are 50% against Absolute Total Shareholder Return ("TSR") performance, and 50% against Earnings per Share ("EPS") performance, as detailed below.
- expiry on the 4th anniversary of the Grant Date, unless an earlier lapsing date applies

#### **TSR**

The TSR formula is:

((Share Price at Test Date – Share Price at Start Date)
+ (\$ Dividends Received))/Share Price at Start Date

The 2018 Performance Rights will be assessed against the following TSR targets:

- For threshold performance: 8% per annum compounded over the Performance Period; and
- For stretch performance: 12% per annum compounded over the Performance Period.

The vesting schedule is as follows, TSR performance over relevant Performance Period:

- Less than 8% per annum compounded -0% of the Performance Rights vest;
- 8% per annum compounded 50% of the Performance Rights vest;
- Between 8% and 12% per annum compounded

   a pro rata number between 50% and 100% of the Performance Rights vest;
- At or above 12% per annum compounded 100% of the Performance Rights vest.

#### EPS

The Company's EPS performance will be measured in the 2020 financial year. For the purposes of performance testing the Performance Rights, EPS in the 2020 financial year will be the Basic EPS for the year, as prescribed by the accounting standards and set out in the Company's Financial Reports, adjusted to remove the following non-cash items from the calculation of profit or loss attributable to ordinary shareholders in the year, in order to reflect the companies underlying profitability:

- (a) amortisation of acquired intangibles;
- (b) unwinding of interest on deferred acquisition consideration payments;
- (c) adjustments to the assessment of deferred consideration payable; and
- (d) acquisition costs.

The 2018 Performance Rights will be assessed against the following TSR targets:

- For threshold performance: EPS of 5.7 cents per share in the year ended 30 June 2020; and
- For stretch performance: EPS of 6.1 cents per share in the year ended 30 June 2020.

The vesting schedule is as follows for the applicable EPS performance over the relevant Performance Period. If EPS in the year ended 30 June 2020 is:

- Less than 5.7 cents per share 0% of the Performance Rights vest;
- 5.7 cents per share 50% of the Performance Rights vest;
- Between 5.7 and 6.1 cents per share—a pro rata number between 50% and 100% of the Performance Rights vest;
- At or above 6.1 cents per share– 100% of the Performance Rights vest.

Once the performance measurement calculation has been finalised the company will allot and issue the equivalent number of shares at nil consideration on the basis of one ordinary share per vested Performance Right for all Performance Rights exercised.

4 Do the \*securities rank equally in all respects from the \*issue date with an existing \*class of quoted \*securities?

If the additional \*securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

5 Issue price or consideration

No.

Prior to vesting, the Performance Rights do not carry a right to vote, receive dividends, or generally participate in corporate actions. When the Performance Rights have vested and are exercised, ordinary fully paid shares are issued which will rank equally with the Company's already quoted securities.

| Jil. |  |  |  |
|------|--|--|--|
|      |  |  |  |

<sup>+</sup> See chapter 19 for defined terms.

6 Purpose of the issue The Performance Rights are being issued under the (If issued as consideration for the Southern Cross Electrical Engineering Limited Senior acquisition of assets, clearly Management Long Term Incentive Plan ("Plan"). identify those assets) The Plan, which was approved by shareholders at the 2017 AGM, seeks to reward performance in support of the achievement of the strategy of the business. Included in the issue are 570,175 FY18 Performance Rights issued to the Managing Director, Graeme Dunn, in accordance with a resolution passed by shareholders at the Company's AGM on 31 October 2017. 6a Yes Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder 31 October 2017 resolution under rule 7.1A was passed 6c Number of \*securities issued Nil without security holder approval under rule 7.1 6d Number of \*securities issued with security holder approval under rule 7.1A 6e Number of \*securities issued Nil with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) 6f 1,241,118 Number of \*securities issued under an exception in rule 7.2 N/a 6g If \*securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.

6h If \*securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

| N/a |  |  |  |  |
|-----|--|--|--|--|
|     |  |  |  |  |
|     |  |  |  |  |
|     |  |  |  |  |
|     |  |  |  |  |

6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

Remaining 7.1 capacity – 28,070,864 Remaining 7.1A capacity – 18,713,909

7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

7 November 2017

8 Number and \*class of all \*securities quoted on ASX (*including* the \*securities in section 2 if applicable)

| Number      | *Class          |      |          |
|-------------|-----------------|------|----------|
| 187,139,097 | Fully<br>shares | paid | ordinary |

9 Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)

| Number    | <sup>+</sup> Class                        |
|-----------|---|
| 2,678,311 | Financial Year 2016<br>Performance Rights |
| 1,310,069 | Financial Year 2017<br>Performance Rights |
| 1,241,118 | Financial Year 2017<br>Performance Rights |

<sup>+</sup> See chapter 19 for defined terms.

| 10     | Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)   | N/a |
|--------|--|-----|
| Part 2 | e - Pro rata issue   |     |
| 11     | Is security holder approval required?  | N/a |
| 12     | Is the issue renounceable or non-renounceable?   | N/a |
| 13     | Ratio in which the *securities will be offered   | N/a |
| 14     | <sup>+</sup> Class of <sup>+</sup> securities to which the offer relates   | N/a |
| 15     | <sup>+</sup> Record date to determine entitlements   | N/a |
| 16     | Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?   | N/a |
| 17     | Policy for deciding entitlements in relation to fractions  | N/a |
| 18     | Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7. | N/a |
| 19     | Closing date for receipt of acceptances or renunciations   | N/a |
| 20     | Names of any underwriters  | N/a |
| 21     | Amount of any underwriting fee or commission   | N/a |
| 22     | Names of any brokers to the issue  | N/a |

| 23 | Fee or commission payable to the broker to the issue  | N/a |
|----|---|-----|
| 24 | Amount of any handling fee<br>payable to brokers who lodge<br>acceptances or renunciations on<br>behalf of security holders   | N/a |
| 25 | If the issue is contingent on security holders' approval, the date of the meeting   | N/a |
| 26 | Date entitlement and acceptance<br>form and offer documents will be<br>sent to persons entitled   | N/a |
| 27 | If the entity has issued options,<br>and the terms entitle option<br>holders to participate on exercise,<br>the date on which notices will be<br>sent to option holders | N/a |
| 28 | Date rights trading will begin (if applicable)  | N/a |
| 29 | Date rights trading will end (if applicable)  | N/a |
| 30 | How do security holders sell their entitlements <i>in full</i> through a broker?  | N/a |
| 31 | How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?   | N/a |
| 32 | How do security holders dispose of their entitlements (except by sale through a broker)?  | N/a |
| 33 | <sup>+</sup> Issue date   | N/a |

## Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

Type of \*securities (*tick one*)

<sup>+</sup> See chapter 19 for defined terms.

| (a)               | *Securities described in Part 1  |
|-------------------|--|
| (b)               | All other *securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities |
| Entities          | s that have ticked box 34(a)   |
| Additio           | onal securities forming a new class of securities  |
| Tick to<br>docume | indicate you are providing the information or  |
| 35                | If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders  |
| 36                | If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories  1 - 1,000  1,001 - 5,000  5,001 - 10,000  10,001 - 100,000  100,001 and over                                     |
| 37                | A copy of any trust deed for the additional *securities  |
| Entities          | s that have ticked box 34(b)   |
| 38                | Number of *securities for which *quotation is sought N/a   |
| 39                | <sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought  |

| 40 | Do the *securities rank equally in<br>all respects from the *issue date<br>with an existing *class of quoted<br>*securities?   | N/a    |        |
|----|--|--------|--------|
|    | If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment |        |        |
| 41 | Reason for request for quotation now   | N/a    |        |
|    | Example: In the case of restricted securities, end of restriction period   |        |        |
|    | (if issued upon conversion of<br>another *security, clearly identify<br>that other *security)  |        |        |
|    |  |        |        |
|    |  | Number | +Class |
| 42 | Number and *class of all *securities quoted on ASX (including the *securities in clause 38)  | N/a    |        |
|    |  |        |        |

### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.

<sup>+</sup> See chapter 19 for defined terms.

• An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 7 November 2017

(Company secretary)

Print name: COLIN HARPER

== == == ==

# Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

## Part 1

| Rule 7.1 – Issues exceeding 15% of capital  |                              |  |
|---|------------------------------|--|
| Step 1: Calculate "A", the base fig capacity is calculated  | ure from which the placement |  |
| Insert number of fully paid <sup>+</sup> ordinary securities on issue 12 months before the <sup>+</sup> issue date or date of agreement to issue  | 159,426,058                  |  |
| Add the following:  |                              |  |
| Number of fully paid <sup>+</sup> ordinary<br>securities issued in that 12 month<br>period under an exception in rule 7.2   | 232,879                      |  |
| Number of fully paid <sup>+</sup> ordinary<br>securities issued in that 12 month<br>period with shareholder approval  | 27,480,160                   |  |
| Number of partly paid <sup>+</sup> ordinary<br>securities that became fully paid in that<br>12 month period   |                              |  |
| <ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> |                              |  |
| Subtract the number of fully paid +ordinary securities cancelled during that 12 month period  | Nil                          |  |
| "A"   | 187,139,097                  |  |

<sup>+</sup> See chapter 19 for defined terms.

| Step 2: Calculate 15% of "A"  |   |  |  |
|---|---|--|--|
| "B"   | 0.15  |  |  |
|   | [Note: this value cannot be changed]                            |  |  |
| Multiply "A" by 0.15  | 28,070,864  |  |  |
| Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used   |   |  |  |
| <b>Insert</b> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:  | Nil   |  |  |
| <ul> <li>Under an exception in rule 7.2</li> </ul>  |   |  |  |
| Under rule 7.1A   |   |  |  |
| <ul> <li>With security holder approval under<br/>rule 7.1 or rule 7.4</li> </ul>  |   |  |  |
| <ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> |   |  |  |
| "C"   | Nil   |  |  |
| Step 4: Subtract "C" from ["A" x " placement capacity under rule 7.1  | B"] to calculate remaining                                      |  |  |
| "A" x 0.15  | 28,070,864  |  |  |
| Note: number must be same as shown in<br>Step 2   |   |  |  |
| Subtract "C"  | Nil   |  |  |
| Note: number must be same as shown in<br>Step 3   |   |  |  |
| Total ["A" x 0.15] – "C"  | 28,070,864  |  |  |
|   | [Note: this is the remaining placement capacity under rule 7.1] |  |  |

| Rule 7.1A – Additional placement capacity for eligible entities  Step 1: Calculate "A", the base figure from which the placement capacity is calculated   |   |  |
|---|---|--|
|   |   |  |
| Step 2: Calculate 10% of "A"  | T                                       |  |
| "D"   | 0.10 Note: this value cannot be changed |  |
| Multiply "A" by 0.10  | 18,713,909                              |  |
| Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used  |   |  |
| <ul> <li>Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A</li> <li>Notes:         <ul> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> </ul> | Nil                                     |  |
| "E"   | Nil                                     |  |

<sup>+</sup> See chapter 19 for defined terms.

| Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A |  |
|---|--|
| "A" x 0.10  | 18,713,909   |
| Note: number must be same as shown in Step 2  |  |
| Subtract "E"  | Nil  |
| Note: number must be same as shown in Step 3  |  |
| <b>Total</b> ["A" x 0.10] – "E"   | 18,713,909   |
|   | Note: this is the remaining placement capacity under rule 7.1A |